Ann: Launch of IBM Case Study, page-13

Fantastic. The beginnings of a considerable re-rate. I bought in a month ago for the April roadshow and presentation, so this news, while surprising, is just another compelling reason to invest.

♦ http://healthsciences.curtin.edu.au/faculty-news/pvc-message-may-2016/sop-app/

♦ Support from the CSIRO, Alzheimer's Australia AND the Dementia Society of America.

♦ Upcoming implementation studies with industry partners, including Bupa. (Bupa has revenue of £9.8 billion GBP)

♦ EPT has signed a binding MoU with Strenuus, a UK-based insurance counter-fraud group, with the intention of developing a scalable anti-fraud medical-legal assessment platform through the integration of ePATs capabilities within Strenuus behavioural assessment platform.

♦ If the development of the platform proves successful, this could potentially open up ePAT to the insurance counter-fraud market in the UK and globally.

♦ According to a report of the Association of British Insurers dated December 2013, whiplash claims cost the UK insurance industry L2 billion (A$3.9 billion) a year.

♦ First mover advantage http://www.smh.com.au/federal-polit...ng-under-turnbull-scheme-20161203-gt39s7.html

♦ The government, which is chipping in $70 million, hopes the fund will turn innovative start-ups into businesses that create jobs and boost exports. Projects include ePAT, real-time facial recognition technology that assesses pain in people who cannot communicate verbally.

♦ A report commissioned by Alzheimer's Australia, released yesterday, indicates that this year, dementia is estimated to cost Australia $14.67 billion

♦ https://www.fightdementia.org.au/The-economic-cost-of-dementia-in-Australia-2016-to-2056.pdf

♦ This is projected to be $36.85 billion a year by 2056. Costing Australia a massive $1.033 trillion over the next 40 years.

♦ Market cap ~$16 million, with cash in the bank of ~$3.5 million, and low cash burn. Development of the app is cost-effective, and highly scalable.

♦ The board are all medical professionals or established doctors - significant experience including Cochlear, Resmed and Roche.

♦ Full results of the implementation study will be presented at the 2017 Australian Pain Society 37th Annual Scientific Meeting in April, where ePAT will also be presenting as a company for the first timein front of an international audience. Expect a big re-rate to occur when this happen and news disseminates.

♦ https://www.dcconferences.com.au/aps2017/

♦ My conservative estimation of fair value is 10c per share. With the right news and go-to-market strategy, on top of this IBM partnership to develop the AI 'under the hood', could see this emulate the RAP run. Especially if they crack the counter-fraud insurance market.